Rezdiffra (Resmetirom) International Purchase Legalities

What Is Rezdiffra and Why Does Its Legal Status Matter?

Rezdiffra is the brand name for resmetirom, a liver-directed thyroid hormone receptor beta (THR-β) selective agonist developed by Madrigal Pharmaceuticals. The FDA granted accelerated approval on March 14, 2024, making it the first drug ever approved specifically for metabolic dysfunction-associated steatohepatitis (MASH, previously called NASH) with moderate-to-advanced liver fibrosis (stages F2 and F3) [1]. Because approval is limited to the United States, questions about buying it abroad are both medically and legally complicated.

How MAESTRO-NASH Established the Evidence Base

The key MAESTRO-NASH trial (N=966, 52 weeks) compared resmetirom 80 mg and 100 mg daily against placebo in adults with biopsy-confirmed MASH [2]. The 100 mg dose achieved NASH resolution without worsening fibrosis in 25.9% of participants versus 14.2% for placebo (P<0.001). One-stage-or-greater fibrosis improvement occurred in 26.0% of the 100 mg group versus 14.2% placebo (P<0.001). These dual-endpoint findings formed the basis of the FDA submission.

Accelerated Approval and Its Implications

Because the FDA granted accelerated approval, Madrigal must complete a confirmatory outcomes trial (MAESTRO-NASH OUTCOMES) to verify clinical benefit [3]. Accelerated approval does not diminish legality or clinical standing, but it does mean the drug could theoretically be withdrawn if confirmatory data disappoint. Patients and physicians should track trial progress when making long-term treatment decisions.

The FDA label restricts use to adults with noncirrhotic MASH and F2 or F3 fibrosis confirmed by biopsy or accepted non-invasive testing [1]. Use outside those criteria is off-label.

U.S. Federal Law on Prescription Drug Importation

Buying Rezdiffra from a foreign pharmacy and shipping it to a U.S. Address is illegal in most circumstances. That sentence is blunt, but accurate.

The Statutory Framework

The Federal Food, Drug, and Cosmetic Act (FDCA) generally prohibits importation of unapproved drugs into the United States [4]. Because Rezdiffra is approved only by the FDA and manufactured for the U.S. Market under specific cGMP conditions, a version obtained from a foreign source is legally treated as an unapproved drug even if it is chemically identical. The FDA's Importation FAQ reinforces this point [4].

Personal-Use Enforcement Discretion

The FDA has maintained a long-standing enforcement-discretion policy allowing customs agents to exercise judgment on small personal-use quantities, typically described as a 90-day supply, when the drug is not commercially available domestically and is for a serious condition [4]. Rezdiffra fails the "not commercially available domestically" test because it is actively marketed in the U.S. That exclusion matters. Patients who attempt to import Rezdiffra citing personal-use discretion are taking a legal risk that most immigration attorneys and the FDA itself would not endorse.

State-Level Re-importation Programs

Several U.S. States, including Florida and Colorado, received FDA authorization to operate Section 804 Importation Programs (SIPs) allowing importation from Canada [5]. As of mid-2026, these programs cover specific drugs on a state-approved formulary. Resmetirom is not currently listed on any active SIP formulary, partly because it has no Canadian approval. Patients should monitor FDA's SIP page for updates [5].

International Regulatory Status of Resmetirom in 2026

As of the article's last review date, resmetirom holds regulatory approval only in the United States. Understanding where the drug stands elsewhere directly shapes what "international purchase" means in practice.

European Medicines Agency (EMA)

Madrigal submitted a Marketing Authorization Application to the EMA. The EMA's Committee for Medicinal Products for Human Use (CHMP) was in active review as of early 2026. No approval had been granted. Patients in EU member states cannot legally obtain resmetirom through domestic pharmacies [6].

Canada and the UK

Health Canada had not approved resmetirom as of mid-2026. The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK was conducting a parallel scientific assessment. Without local approval in either country, pharmacies there cannot legally dispense the drug, meaning the "buy from Canada" route that some patients use for other medications does not apply here [6].

Gray-Market and Unverified Online Pharmacies

Patients sometimes find websites claiming to sell resmetirom from India, Turkey, or other manufacturing hubs. These sources are not regulated for quality, dosing accuracy, or supply-chain integrity. The FDA's BeSafeRx campaign specifically warns against online pharmacies that do not require a valid U.S. Prescription or that operate outside NABP-accredited networks [4]. Counterfeit or substandard resmetirom could deliver incorrect doses to a patient with already-compromised liver function, a scenario with serious safety implications.

How to Get Rezdiffra at a Lower Cost Through Legal U.S. Channels

The wholesale acquisition cost (WAC) of Rezdiffra is approximately $47,400 per year. Out-of-pocket exposure varies widely by insurance, but several programs can bring that cost down substantially.

Madrigal REZDIFFRA Support Program

Madrigal operates a dedicated patient-support program. Commercially insured patients who meet income criteria may qualify for $0 copay through the manufacturer's copay assistance card [7]. Uninsured or underinsured patients can apply for free drug through the Patient Assistance Program (PAP). Eligibility thresholds and application materials are available through Madrigal's access team; prescribers can initiate enrollment at the point of prescribing.

Key points for the support program:

• Copay cards typically cannot be used by Medicare or Medicaid beneficiaries due to federal anti-kickback rules [8].
• PAP eligibility is reviewed annually and requires documentation of income and insurance status.
• The specialty-pharmacy network for Rezdiffra is limited; patients are generally required to use Madrigal's designated specialty pharmacies.

Insurance Coverage and Prior Authorization

Most commercial plans that cover specialty biologics require prior authorization for Rezdiffra. Typical requirements include a confirmed MASH diagnosis (biopsy or validated non-invasive score), documented fibrosis stage of F2 or F3, and a prescribing gastroenterologist or hepatologist. The American Association for the Study of Liver Diseases (AASLD) guidance on MASH management supports pharmacotherapy in patients meeting those criteria [9].

If an insurer denies coverage, patients have the right to an internal appeal and, after exhausting that, an independent external review under the Affordable Care Act. Denials based on "investigational" classifications can be challenged by citing the FDA approval date and the MAESTRO-NASH trial data [2].

340B Pricing

Patients receiving care at a federally qualified health center (FQHC) or other 340B-covered entity may access resmetirom at the 340B ceiling price, which is substantially below WAC. The Health Resources and Services Administration (HRSA) maintains the 340B program; eligibility is institutional, not individual [10]. Ask your hepatology or gastroenterology clinic directly whether they participate.

Pharmacy Benefit Manager (PBM) Negotiations and Formulary Tiers

Large PBMs negotiate rebates with manufacturers. Where Rezdiffra lands on a formulary tier directly determines patient cost-sharing. Tier 3 specialty placement is common. Tier exceptions requests, supported by a letter of medical necessity from your prescriber, can sometimes move the drug to a lower cost-sharing tier. The prescriber letter should reference fibrosis stage, ALT trajectory, and the absence of alternative approved therapies with a comparable evidence base.

Can I Use HSA or FSA Funds for Rezdiffra?

Yes. Rezdiffra is a prescription medication for a diagnosed medical condition (MASH with F2/F3 fibrosis), which means it qualifies as a medical expense under IRS Publication 502 [11]. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay copays, deductibles, or any out-of-pocket cost associated with the prescription.

HSA vs. FSA: Practical Differences for a High-Cost Drug

HSA funds roll over year to year, making them better suited to a high-cost chronic therapy. FSA funds generally must be spent within the plan year (with a limited grace period or $610 rollover under IRS rules for 2026). For a drug costing tens of thousands of dollars annually, an HSA paired with a high-deductible health plan may provide the most tax-efficient path to covering out-of-pocket costs [11].

The IRS does not maintain a specific approved-drug list for HSA/FSA eligibility; any prescription drug prescribed by a licensed provider qualifies. Keep pharmacy receipts and explanation-of-benefits (EOB) statements for documentation if audited.

Limited-Purpose FSAs

Patients enrolled in an HSA-compatible high-deductible health plan (HDHP) who also have a limited-purpose FSA (LPFSA) should note that LPFSAs are restricted to dental and vision expenses until the HDHP deductible is met. Rezdiffra costs cannot be paid from an LPFSA in the pre-deductible phase [11].

Clinical Context: Who Qualifies for Rezdiffra?

The FDA label is specific [1]. Rezdiffra is indicated for adults with noncirrhotic MASH who have liver fibrosis at stage F2 or F3, confirmed by biopsy or acceptable non-invasive assessment. Stage F4 (cirrhosis) is excluded.

Non-Invasive Fibrosis Assessment

The 2023 AASLD Practice Guidance states: "Non-invasive tests, including FIB-4 index and liver stiffness measurement by elastography, may be used to estimate fibrosis stage and select patients for pharmacotherapy when biopsy is not feasible or acceptable to the patient" [9]. A FIB-4 score above 2.67 has a positive predictive value of approximately 80% for advanced fibrosis (F3/F4) in MASH populations [12].

Dose Selection

The approved doses are 80 mg daily (for patients below 100 kg) and 100 mg daily (for patients at or above 100 kg), both taken orally with food. The MAESTRO-NASH trial used these weight-based thresholds [2]. Dose modification for mild-to-moderate hepatic impairment is addressed in the prescribing information; severe hepatic impairment data are limited.

Monitoring Parameters

Liver enzymes (ALT, AST) typically improve within the first 12 weeks of therapy. The prescribing information recommends assessment at baseline, 12 weeks, and then periodically. LDL cholesterol rises modestly (mean increase approximately 16% in the 100 mg arm at 52 weeks) due to the THR-β mechanism affecting cholesterol metabolism [1]. Lipid panels should be checked and managed accordingly.

What Patients and Prescribers Should Do Right Now

The practical answer to the international-purchase question is direct: legal routes do not currently exist for obtaining resmetirom outside the United States, and domestic programs offer meaningful cost relief. The action items below summarize the most evidence-supported approach.

For Patients Without Insurance Coverage

Apply to the Madrigal PAP before paying out of pocket. Document MASH diagnosis and fibrosis stage with your hepatologist's notes. If you receive care at a safety-net hospital or FQHC, ask explicitly whether the institution participates in 340B pricing for this drug [10].

For Patients With Commercial Insurance

Confirm prior-authorization requirements before the prescription is submitted. Supply your prescriber with your biopsy report or FIB-4/elastography results. Use the Madrigal copay card if eligible. Max out HSA contributions for the plan year if you expect significant out-of-pocket exposure, because the IRS 2026 HSA contribution limit for self-only HDHP coverage is $4,300 [11].

For Prescribers

The AASLD and the European Association for the Study of the Liver (EASL) both recognize MASH with significant fibrosis as a condition warranting treatment when pharmacotherapy is available [9]. Accurate fibrosis staging documentation in the chart strengthens prior-authorization success and protects the patient's access to the drug long-term.

Prescribers should also be aware that resmetirom carries a THR-β-related warning about potential thyroid-stimulating effects; thyroid function should be assessed in patients with pre-existing thyroid disease before initiating therapy [1].